Azitra (AZTR) Preferred Stock Liabilities (2022 - 2023)

Azitra (AZTR) posted Preferred Stock Liabilities of $3.3 million for Q1 2023, down 79.95% on a QoQ basis from $16.3 million in Q4 2022.

Azitra (AZTR) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends

Azitra's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $3.3 million for Q1 2023.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $3.3 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $3.3 million (changed N/A YoY) and the FY2022 annual result came in at $16.3 million, changed N/A from the prior year.
Preferred Stock Liabilities was $3.3 million for Q1 2023 at Azitra, down from $16.3 million in the prior quarter.
Across five years, Preferred Stock Liabilities topped out at $16.3 million in Q4 2022 and bottomed at $3.3 million in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Nanobiotix	1,792.52 Bn	1,792.46 Bn	-	-
2	Akari Therapeutics	999.95 Bn	999.95 Bn	-	-
3	BeOne Medicines	475.97 Bn	471.17 Bn	1.35 Bn	-
4	Vertex Pharmaceuticals	124.91 Bn	117.66 Bn	2.59 Bn	-
5	Regeneron Pharmaceuticals	72.31 Bn	63.56 Bn	3.31 Bn	-
6	Belite Bio	62.01 Bn	62.01 Bn	-	-
7	Argenx Se	54.23 Bn	49.04 Bn	1.41 Bn	-
8	Alnylam Pharmaceuticals	38.31 Bn	35.30 Bn	959.66 Mn	-
9	Revolution Medicines	36.16 Bn	36.16 Bn	-	-
10	Azitra	2.05 Mn	2.05 Mn	-	-

Download Data

Date	Value
Mar 31, 2023	3.27 Mn
Dec 31, 2022	16.32 Mn